Zoetis Inc (NYSE:ZTS) tumbled to a 52-week low after a media report suggested the company’s arthritis shots, Librela and Solensia, could have sickened dogs and cats. Solensia (frunevetmab) gained FDA approval in January 2022 for pain associated with osteoarthritis in cats. It became the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  In May 2023, the FDA approved Librela (bedinvetmab) for pain associated with osteoarthritis in dogs. Librela is the first mAb the FDA has approved for use in dogs. Also Read: Animal Health-Focused Zoetis Stock Faces Near-Term Pressure, Analyst Cites Uncertainty ...